Skycure Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.63 M
as on 16-11-2024
- Revenue -39.39%
(FY 2023)
- Profit -141.41%
(FY 2023)
- Ebitda -291.43%
(FY 2023)
- Net Worth -62.69%
(FY 2023)
- Total Assets -18.71%
(FY 2023)
About Skycure Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.63 M.
Mritunjay Singh, Lalbabu Thakur, Amit Singh, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232GJ2014PTC081549
- Company No.
081549
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Dec 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Gandhi Nagar, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Skycure Lifesciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mritunjay Singh  | Director | 15-Dec-2014 | Current |
| Lalbabu Thakur | Director | 15-Dec-2014 | Current |
| Amit Singh | Director | 15-Dec-2014 | Current |
| Gayatri Patel | Director | 10-Mar-2015 | Current |
Financial Performance of Skycure Lifesciences.
Skycure Lifesciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 39.39% decrease. The company also saw a substantial fall in profitability, with a 141.41% decrease in profit. The company's net worth observed a substantial decline by a decrease of 62.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skycure Lifesciences?
In 2023, Skycure Lifesciences had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Skysun Lifesciences Private LimitedActive 11 years 5 monthsMritunjay Singh, Lalbabu Thakur and 2 more are mutual person
Charges (Loans)
₹0.63 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.06 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 May 2015 | Others | ₹0.63 M | Open |
How Many Employees Work at Skycure Lifesciences?
Unlock and access historical data on people associated with Skycure Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skycure Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skycure Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
